



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Khan et al.

Serial No.: 10/029,206

Filed: December 21, 2001

For: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Confirmation No.: 5353

Examiner: J. Witz

Group Art Unit: 1651

Attorney Docket No.: 2183-5222US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV669814417US

Date of Deposit with USPS: June 12, 2006

Person making Deposit: Tim Palfreyman

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed foreign patent documents and non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 6,727,227	04-27-2004	Khavinson

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 01/29067	04-26-2001	Obschestvo S Ogranichennoi Otvetstvennostiju "Klinika Instituta Bioregulyatsii I Gerontologii"

Other Documents

KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, January 2002, pp. 1-5, Vol. 133, No. 1.

KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, Vol. 137, No. 5.

MOROZOV et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, Vol. 19, No. 9/10.

KHAVINSON et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5.

KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1.

KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4.

KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6.

IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39.

KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 2183-4799.1US
Serial No.: 11/037,972
Filing Date: 1/18/2005
Title: IMMUNOREGULATOR

Attorney Docket No.: 3077-6418US
Serial No.: 11/243,438
Filing Date: 10/4/2005
Title: COMPOSITIONS FOR MUCOSAL AND ORAL
ADMINISTRATION COMPRISING HCG FRAGMENTS

Attorney Docket No.: 3077-6420.2US
Serial No.: 11/249,541
Filing Date: 10/13/2005
Title: COMPOSITIONS CAPABLE OF REDUCING ELEVATED
BLOOD UREA CONCENTRATION

Attorney Docket No.: 3077-7568US
Serial No.: 11/286,571
Filing Date: 11/23/2005
Title: COMPOUNDS OF THERAPEUTIC VALUE IN THE
TREATMENT OF MULTIPLE SCLEROSIS AND OTHER
DISEASES WHEREIN FOAM CELLS ARE INVOLVED IN THE
DISEASE ETIOLOGY


Attorney Docket No.: 3077-7643US
Serial No.: 11/346,450
Filing Date: 2/2/2006
Title: COMPOSITIONS CAPABLE OF REDUCING ELEVATED
BLOOD UREA CONCENTRATION

Serial No.: 10/029,206

Attorney Docket No.: 3077-7568.1US
Serial No.: 11/346,761
Filing Date: 2/3/2006
Title: COMPOUNDS OF THERAPEUTIC VALUE IN THE
TREATMENT OF MULTIPLE SCLEROSIS AND OTHER
DISEASES WHEREIN FOAM CELLS ARE INVOLVED IN THE
DISEASE ETIOLOGY

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,



Li Feng, Ph.D.
Registration No. 57,292
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: June 12, 2006
LF/bv

Enclosures: Form PTO/SB/08
Copy of documents cited
Document in ProLaw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/029,206
Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	1651
Examiner Name	J. Witz
Attorney Docket Number	2183-5222US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 223131450.



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/029,206
Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	1651
Examiner Name	J. Witz
Attorney Docket Number	2183-5222US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T ²
		KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, January 2002, pp. 1-5, Vol. 133, No. 1.	
		KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, Vol. 137, No. 5.	
		MOROZOV et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, Vol. 19, No. 9/10.	
		KHAVINSON et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5.	
		KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1.	
		KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4.	
		KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6.	
		IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39.	
		KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 223131450.